Archives

  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Y-27632 dihydrochloride: Selective ROCK1/2 Inhibitor for ...

    2025-11-05

    Y-27632 dihydrochloride: Selective ROCK1/2 Inhibitor for Rho/ROCK Pathway Studies

    Executive Summary: Y-27632 dihydrochloride is a potent, cell-permeable inhibitor of Rho-associated protein kinases ROCK1 (IC50 ≈ 140 nM) and ROCK2 (Ki ≈ 300 nM), with >200-fold selectivity over kinases such as PKC and PKA (ApexBio A3008 | Wang et al., 2025). It effectively disrupts Rho-mediated stress fiber formation and modulates cell cycle progression and cytokinesis. Y-27632 enhances stem cell viability, supports advanced tissue/organoid models, and suppresses tumor invasion in vitro and in vivo. Its solubility and stability parameters enable robust, reproducible integration into diverse research protocols.

    Biological Rationale

    Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases that regulate actin cytoskeleton dynamics, cell contraction, migration, proliferation, and apoptosis. The Rho/ROCK pathway is crucial in processes such as stress fiber formation, focal adhesion assembly, and cytokinesis. Aberrant ROCK activity is implicated in tumor progression, metastasis, fibrosis, and neurological disorders (Wang et al., 2025). Selective inhibition of these kinases enables mechanistic dissection of cytoskeletal and cell cycle processes, and forms the basis for regenerative, cancer, and stem cell research (see related: Y-27632 Dihydrochloride: Advanced Insights; this article provides new quantitative evidence and solubility guidelines not covered in prior reviews).

    Mechanism of Action of Y-27632 dihydrochloride

    Y-27632 dihydrochloride is a small-molecule ATP-competitive inhibitor that binds to the catalytic domains of ROCK1 and ROCK2. By blocking ATP binding, it suppresses kinase activity, resulting in downstream inhibition of myosin light chain phosphorylation, actin stress fiber formation, and contractility. The compound displays high selectivity (>200-fold) against unrelated kinases such as protein kinase C (PKC), cAMP-dependent protein kinase (PKA), myosin light chain kinase (MLCK), and p21-activated kinase (PAK) (ApexBio A3008). This selectivity minimizes off-target effects and allows precise modulation of the Rho/ROCK pathway in both 2D and 3D culture systems.

    Evidence & Benchmarks

    • Y-27632 inhibits ROCK1 activity with an IC50 of ~140 nM and ROCK2 with a Ki of ~300 nM in vitro (ApexBio).
    • Over 200-fold selectivity for ROCK1/2 versus PKC, PKA, MLCK, and PAK is demonstrated in kinase panels (ApexBio).
    • Y-27632 disrupts Rho-induced stress fiber formation in fibroblasts within 1 hour at concentrations ≥10 μM (Wang et al., 2025).
    • Enhances survival and viability of human expanded pluripotent stem cells (hEPSCs) during passaging and organoid formation (Wang et al., 2025).
    • Reduces prostatic smooth muscle cell proliferation in vitro in a concentration-dependent manner (ApexBio).
    • Suppresses pathological structure formation and metastatic spread in mouse tumor invasion models (ApexBio).
    • Widely adopted for cytoskeletal studies, cell cycle analysis, and regenerative medicine platforms (see also: Selective ROCK Inhibitor for Rho/ROCK Studies; this article updates with new in vivo antitumoral benchmarks).

    Applications, Limits & Misconceptions

    Y-27632 dihydrochloride is extensively used in the following contexts:

    • Stem Cell Viability: Enhances survival and passaging efficiency of hPSCs and hEPSCs in single-cell suspensions and organoid models (Wang et al., 2025).
    • Cytoskeletal Regulation: Inhibits Rho-mediated actin stress fiber assembly, facilitating studies of cell morphology, adhesion, and migration.
    • Oncology Research: Reduces tumor cell invasion and metastasis in vitro and in vivo (ApexBio).
    • Cell Proliferation and Cytokinesis: Modulates G1/S transition and inhibits cytokinesis, enabling cell cycle investigations.
    • Organoid and Regeneration Models: Integrated into 3D culture protocols for sensitive compound testing during chondrogenic differentiation (Wang et al., 2025).
    • Epigenetics & Barrier Research: Recent studies highlight applications in DNA methylation and gut barrier models (see related: Epigenetics and Disease Modeling; this article expands with solubility and selectivity data).

    Common Pitfalls or Misconceptions

    • Y-27632 does not inhibit unrelated kinase families (e.g., MAPKs, PI3K) at working concentrations; lack of effect in non-ROCK-driven pathways is expected.
    • Long-term storage of Y-27632 in solution at room temperature leads to degradation; recommended to store aliquots below -20°C and avoid repeated freeze-thaw cycles (ApexBio).
    • Ineffective in contexts where cytoskeletal changes are ROCK-independent (e.g., dominant Rac1/Cdc42 signaling).
    • Not suitable as a general apoptosis inhibitor; its effect on cell survival is context- and cell-type-dependent.
    • High concentrations (>100 μM) may have off-target effects not observed at standard working doses (1–50 μM).

    Workflow Integration & Parameters

    Solubility Profile: Y-27632 is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water. Solubility may be enhanced by warming to 37°C or brief sonication. Stock solutions (e.g., 10 mM in DMSO) should be stored in aliquots below -20°C for up to several months; avoid prolonged exposure to air/moisture. The solid compound should be stored desiccated at 4°C or below. (ApexBio)

    Experimental Use: Typical working concentrations range from 1 to 50 μM. For dissociation and passaging of hPSCs/hEPSCs, 10 μM is commonly used. For inhibition of actin stress fibers, 10–30 μM is effective. In 3D organoid models, concentration and exposure duration should be optimized according to the stage of differentiation (Wang et al., 2025).

    Integration in Multi-Compound Screens: Y-27632 is compatible with most cell culture media and can be included in compound libraries for high-content screening. However, it should not be combined with strong oxidizers or agents that destabilize kinase inhibitors.

    For protocol examples and workflow troubleshooting, see Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Advanced Workflows. This article emphasizes new evidence on solubility and storage stability not provided in prior workflow summaries.

    Conclusion & Outlook

    Y-27632 dihydrochloride remains a reference-standard, selective ROCK1/2 inhibitor for dissection of Rho/ROCK signaling in cell and tissue models. Its high potency, selectivity, and favorable solubility profile support broad experimental use from cytoskeletal to cancer and stem cell applications. Ongoing research is expanding its utility in precision disease modeling, organoid systems, and regenerative medicine. For current specifications, protocols, and ordering, see the A3008 product page.